<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733382</url>
  </required_header>
  <id_info>
    <org_study_id>212110</org_study_id>
    <nct_id>NCT00733382</nct_id>
  </id_info>
  <brief_title>Effect of Dexamethasone on Migraine Headache</brief_title>
  <official_title>The Effect of Dexamethasone in the Attack of Migraine Headache and to Prevent of Its Relapse After Discharge From Emergency Department: a Randomized, Double-Blind, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexamethasone is a safe and cheap abortive therapy for migraine headache. The effect of it is
      never evaluate and not correlate with the effect of popular anti migraine medication such as
      dihydroergotamine. The investigators proposal is to compare its effect with
      dihydroergotamine.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the efficacy of dexamethazone in abortive therapy of migraine attack and prevent of recurrence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethazone</intervention_name>
    <description>injection form, 8 miligram, injected once</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Migraine attack according to international headache society criteria

          2. Migraine without aura; at least 5 attack with mean duration of 4 to 72 hours and 2 of
             following:

               -  Unilateral

               -  Pulsatile

               -  Severe enough to impair daily activity

               -  Aggravate with walking and climbing, also 1 of following:

                    -  Nausea and or vomiting

                    -  Photophobia and phonophobia, and not contributed to other headache.

          3. Migraine with aura; at least 2 attacks with 3 of following:

               -  One reversible aura

               -  Aura became apparent at least in 4 minutes

               -  Aura not lasting more than 60 minutes

               -  Headache develops in less than 60 minutes after aura

        Exclusion Criteria:

          1. Hypertension

          2. Ischemic heart disease

          3. Basilar migraine with sign and symptoms such as:

               -  Diplopia

               -  Ataxia

               -  Dysarthria

               -  Dysphagia

               -  Weakness

               -  Sensory disorder

               -  Drowsiness

          4. Peripheral vascular disease

          5. Sepsis

          6. Age more than 40 and less than 15 year old

          7. Pregnancy

          8. Use of triptans and ergots derivatives in past 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peyman Petramfar</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <last_update_submitted>August 11, 2008</last_update_submitted>
  <last_update_submitted_qc>August 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Reza Nemati/research manager of neurology department</name_title>
    <organization>Shiraz university of medical sciences</organization>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>dihydroergotamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

